[1]Zhang Y, Geng C, Liu X, et al. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1[J]. Mol Metab,2016, 17:138-147. [2]Chen J, Chen H, Pan L. SIRT1 and gynecological malignancies[J]. Oncol Rep,2021,45:43. [3]Purushotham A, Schug TT, Xu Q,et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation[J]. Cell Metab,2009,9:327-338. [4]Chyau CC, Wang HF, Zhang WJ,et al. Antrodan alleviates high-fat and high-iructose diet-induced fatty liver disease in C57BL/6 mice model via AMPK/Sirt1/SREBP-1c/PPARγ pathway[J]. Int J Mol Sci, 2020,21:360-370. [5]Pfluger PT, Herranz D, Velasco-Miguel S, et al. Sirt1 protects against high-fat diet-induced metabolic damage[J]. Proc Natl Acad Sci U S A, 2008,105:9793-9798. [6]de Mingo Á, de Gregorio E, Moles A, et al. Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation[J]. Cell Death Dis,2016,7:2464-2469. [7]de Gregorio E, Colell A, Morales A,et al. Relevance of SIRT1-NF-κB axis as therapeutic target to ameliorate inflammation in liver disease[J]. Int J Mol Sci, 2020,21:3858-3867. [8]Zusso M, Lunardi V, Franceschini D, et al. Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-κB pathway[J]. J Neuroinflammation, 2019,16:148-152. [9]Ding RB, Bao J, Deng CX. Emerging roles of SIRT1 in fatty liver diseases[J]. Int J Biol Sci, 2017,13:852-867. [10] You M, Jogasuria A, Taylor C,et al. Sirtuin 1 signaling and alcoholic fatty liver disease[J]. Hepatobiliary Surg Nutr,2015,4:88-100. |